Product Overview

Zepbound® is a breakthrough once-weekly injection developed by Eli Lilly and Company for chronic weight management and obstructive sleep apnea (OSA) in adults with obesity. By targeting both GIP and GLP-1 receptors, Zepbound reduces appetite, improves satiety, and enhances metabolic control. Clinical trials show average weight loss of up to 20% body weight over 72 weeks, making it one of the most effective therapies for obesity management.

How to Use Zepbound

• Inject once weekly on the same day each week.
• Administer subcutaneously in the abdomen, thigh, or upper arm.
• Rotate injection sites to avoid irritation.
• Pens are single-dose prefilled injectors; each pen delivers one weekly dose.

Dosage and Strengths

• Starter dose: 2.5 mg weekly for 4 weeks (not a maintenance dose).
• Stepwise titration: 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg.
• Available strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg per 0.5 mL pen.

How Zepbound Works

Zepbound activates two gut hormone receptors (GIP and GLP-1). This dual action reduces hunger, increases satiety, and improves glucose metabolism. The result is sustained weight loss and improved cardiometabolic health.

Safety Information

• Common side effects: nausea, vomiting, diarrhea, constipation, decreased appetite.
• Serious risks: pancreatitis, gallbladder disease, thyroid tumors (seen in animal studies).
• Contraindications: history of medullary thyroid carcinoma, MEN2, or hypersensitivity to tirzepatide.
• Not recommended during pregnancy or breastfeeding.

Tips for Best Results

• Use alongside a reduced-calorie diet and increased physical activity.
• Stay hydrated to reduce gastrointestinal side effects.
• Track weight and waist circumference regularly.
• Store pens refrigerated (2–8 °C); do not freeze.

Legal Disclaimer

This product information is provided for educational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Zepbound® is a prescription-only medicine manufactured by Eli Lilly and Company and should be used under medical supervision.